Business Wire

MAXION Flexible Wheel with MICHELIN ACORUS Technology

Del

Innovation has always been part of Michelin’s genetic code – driving mobility and tire developments for more than 100 years. Now with MICHELIN ACORUS Technology, in partnership with Maxion Wheels, Michelin is reinventing the wheel to help eliminate road-based damage to tires and rims.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912006833/en/

The Maxion Flexible Wheel with Michelin Acorus technology is a wheel designed and built to withstand ...

The Maxion Flexible Wheel with Michelin Acorus technology is a wheel designed and built to withstand the toughest road conditions for large diameter, low profile tires. (Photo: Business Wire)

The patented new technology, developed by Michelin and Maxion Wheels for the passenger car wheel market, incorporates two flexible rubber flanges mounted on a special wheel body to create a flexible wheel that improves the ride and comfort and also absorbs impacts from potholes and curbs. The new wheel is compatible with all tires on the market and comprises an alloy rim – which is narrower than normal, two rubber flanges and an optional cosmetic insert to protect the alloy wheel.

Talking about this new innovation, Michelin Chief Operating Officer, Florent Menegaux said: “Car wheels have been getting bigger and bigger, as they contribute to making cars look more premium, and large shiny alloys are an integral part of all modern car designs. However, the resulting low profile tires with short sidewalls are much more susceptible to damage on today’s deteriorating roads with myriad potholes.”

Pieter Klinkers, Maxion Wheels CEO stated: “This is a game changer for wheels; a standard wheel driven through a pothole can damage the tire and potentially crack the alloy rim, putting the safety of driver and passengers at risk. When the Maxion Flexible Wheel hits a pothole, the MICHELIN ACORUS Technology flange flexes and protects the tire and the wheel.”

In tests with a 285/30R21 tire driven through a pothole*, the standard rim version punctured the tire at 28kph whereas the Flexible Wheel with the MICHELIN ACORUS Technology did not puncture, or sustain damage at any speed.

In addition to damage reduction, safety and improved mobility, the Maxion Flexible Wheel with MICHELIN ACORUS Technology has other benefits for the driver. It helps overcome other shortcomings associated with low profile tires with short sidewalls – comfort and noise levels are both improved due to the flexible rubber flange which sits between the wheel and the tire. There is also an environmental benefit in using MICHELIN ACORUS Technology; the Flexible Wheel is designed to work with any brand of tire, including low rolling resistance tires – meaning lower CO2 emissions and better fuel economy. The innovative wheel solution also means fewer damaged tires and wheels are being thrown away following pothole damage.

MICHELIN ACORUS Technology is the product of Michelin’s research Group. The Incubator Program shortened the time to market by showing and testing it with customers. Having designed and developed this unique patented technology, Michelin started to work in partnership with Maxion Wheels, a leader in the wheel business, to bring the Flexible Wheel to market.

The name ACORUS is taken from Acorus Calamus, a wetland plant that looks like a reed, which features in a famous French fable ‘the oak and the reed’ with the wisdom that “a reed bends but does not break”. The Flexible Wheel not only safeguards against potholes and poor roads, but marks an end to the compromise in passenger car wheel design between robustness and premium look.

The Maxion Flexible Wheel with MICHELIN ACORUS Technology, launched at the Frankfurt IAA, will initially be sold in 19” and above sizes to the OE premium automakers by the partnership between MICHELIN and Maxion Wheels.

*80mm deep, 700mm long, 70° impact angle

About Maxion Wheels

Maxion Wheels, a division of IOCHPE-MAXION S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks and trailers. The Company also produces wheels for agriculture and military vehicles, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion is the world's largest wheel manufacturer, producing 56 million wheels per year. The Company serves its global OEM customers from 28 locations in 15 countries on five continents, and has state-of-the-art technical centers in the Americas, Europe and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com.

About Michelin

Michelin, the leading tyre company, is dedicated to enhancing its clients’ mobility, sustainably; designing and distributing the most suitable tyres, services and solutions for its clients’ needs; providing digital services, maps and guides to help enrich trips and travels and make them unique experiences; and developing high-technology materials that serve the mobility industry. Headquartered in Clermont-Ferrand, France, Michelin is present in 170 countries, has 111,700 employees and operates 68 production facilities in 17 countries which together produced 187 million tyres in 2016 (www.michelin.com).

Contact information

Maxion Wheels
Colleen Hanley
Global Director, Marketing and Communications
Tel: +1 (734) 737-5204
Mobile: +1 (248) 916-2477
Email: colleen.hanley@maxionwheels.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pietro Rosa TBM Signs Long-Term Agreement with Pratt & Whitney21.5.2018 15:13Pressemelding

Pietro Rosa TBM (Turbine Blade Manufacturing) today announced that it has signed a 10-year, long-term agreement (LTA) with Pratt & Whitney, a division of United Technologies Corp., to supply airfoil products for both commercial and military engines. The LTA, which may extend to the entire Pietro Rosa TBM Group in Europe and the United States, will support Pratt & Whitney’s F135, PW2000 and the Geared Turbofan™ (GTF) family of engines. This agreement represents a significant step in the collaboration between the two companies, enabling the Pietro Rosa TBM Group to utilize its advanced engineering capabilities and the vertical integration of hot forming, machining and surface finishing technologies. “We’re pleased to sign this agreement with Pietro Rosa,” said Art Erikson, executive director of Strategic Sourcing, Pratt & Whitney. “We have tremendous growth ahead, and suppliers like Pietro Rosa that sign up to our contractual governance, commitment to cost competitiveness and continuous

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with